Fmr LLC grew its position in shares of Axovant Sciences Ltd (NYSE:AXON) by 968.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,235,632 shares of the biotechnology company’s stock after buying an additional 6,558,462 shares during the quarter. Fmr LLC owned approximately 6.74% of Axovant Sciences worth $167,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE raised its stake in shares of Axovant Sciences by 38.9% in the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 2,072 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Axovant Sciences by 20.2% in the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 1,168 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Axovant Sciences in the 1st quarter valued at approximately $219,000. American International Group Inc. raised its stake in shares of Axovant Sciences by 7.1% in the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 998 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Axovant Sciences by 38.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 2,789 shares in the last quarter.

A number of brokerages recently weighed in on AXON. BidaskClub raised Axovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Axovant Sciences in a research note on Wednesday, September 27th. Jefferies Group LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Axovant Sciences in a research note on Wednesday, September 27th. ValuEngine downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, Evercore ISI reissued an “outperform” rating and issued a $9.00 price objective (down from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Four analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the stock. Axovant Sciences currently has an average rating of “Hold” and an average target price of $14.68.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/05/fmr-llc-increases-stake-in-axovant-sciences-ltd-axon.html.

Axovant Sciences Ltd (NYSE AXON) opened at 7.73 on Thursday. The firm has a 50-day moving average price of $16.69 and a 200 day moving average price of $16.69. Axovant Sciences Ltd has a 12 month low of $6.13 and a 12 month high of $27.98. The company’s market capitalization is $831.17 million.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Analysts expect that Axovant Sciences Ltd will post ($2.02) EPS for the current year.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.